Fed. Circ. Kills Mylan's Prilosec Antitrust Claims

Law360, New York (March 8, 2011, 4:01 PM EST) -- The Federal Circuit on Tuesday rejected Mylan Laboratories Inc.'s bid to revive allegations that AstraZeneca AB violated antitrust law by filing sham patent infringement suits to protect its heartburn drug Prilosec.

A three-judge panel of the U.S. Court of Appeals for the Federal Circuit upheld Judge Barbara S. Jones of the U.S. District Court for the Southern District of New York's grant of summary judgment to AstraZeneca and dismissal of Mylan's counterclaims.

Mylan argued before the Federal Circuit on Monday that the antitrust claims shouldn't have...
To view the full article, register now.